Tucked deep in the FDA’s proposed Deeming Regulation, which would assert jurisdiction over cigars, e-cigarettes, and other tobacco products, is a cost-benefit analysis that is setting off alarm bells for public health advocates. The analysis is based on the astonishing premise that the benefits from reductions in smoking have to be discounted significantly to offset the loss in pleasure that smokers suffer when they overcome their addiction. This webinar will explain why the FDA conducts a cost/benefit analysis and why the way in which it is being performed is not in the best interest of the future of federal tobacco product regulation. Speakers are Dr. Frank Chaloupka, Distinguished Professor of Economics, University of Illinois at Chicago and the Director of the Health Policy Center at the Institute for Health Research and Policy; and Desmond Jenson, Staff Attorney, Tobacco Control Legal Consortium.
Calculating the “Benefits” of Smoking: How the FDA’s Economic Model Hinders Tobacco Regulation (2014)
You are here
Thursday, September 25, 2014